Bortezomib Use in MCL

In this phase III trial, 487 patients with newly diagnosed mantle cell lymphoma who were not eligible or not considered for stem-cell transplantation were randomised to receive R-CHOP or VR-CAP.

There was a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (HR, 0.51; p <0.001), a relative improvement of 96%. However, rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.